Editorial Advisory Board Profile:
Adam Goulburn, PhD
General Partner, Lux Capital
Adam invests at the intersection of biology, healthcare, technology and data. He is interested in the digitization of healthcare; genomics; coding biology; the microbiome; bionics and cyborgs; brain-computer interfaces; regenerative medicine; synthetic biology; human performance; and other deep sciences.

Adam was an early investor in Hometeam, which uses technology to improve in-home care for our aging population; Pager, which provides consumers better access to healthcare via mobile devices; Drone Racing League, which brings drone racing to any 3-dimensional location on the planet; as well as Science 37, 3Scan, Authorea, Zipdrug, Aptible and Alluvium. Adam was the founding CEO and investor in Kallyope, which combines bioinformatics, sequencing, neuroimaging and molecular biology to decode the gut-brain axis. He has also worked with Vium, Halo Neuroscience and Kyruus.

Prior to joining Lux in 2011, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative stem cell medicine in association with brain disorders such as schizophrenia and Alzheimer’s disease. Originally from Australia, Adam has dual undergraduate degrees in Business and Science and a PhD from the Australian Stem Cell Centre, where he was a Premier Scholar. He has been published in numerous peer-reviewed, scientific journals.